GBMRP FY24_RFI FINAL_for SAM.gov.docx

GBMRP Survey Monkey Subject: Glioblastoma Research Program Fiscal Year 2024 Stakeholder Request for Information

THIS IS NOT A REQUEST FOR PROPOSALS, RFP, OR A REQUEST FOR QUOTATIONS; IT IS STRICTLY A REQUEST FOR INFORMATION, RFI. NEITHER UNSOLICITED PROPOSALS NOR ANY OTHER KINDS OF OFFERS WILL BE CONSIDERED IN RESPONSE TO THIS RFI. NO CONTRACT WILL BE AWARDED PURSUANT TO THIS ANNOUNCEMENT.

1.0 DISCLAIMER: This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. The government reserves the right to use any information submitted in public documents or websites. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for a future RFP will not be entertained. The information which is being requested shall be entered into Survey Monkey; therefore, the government is unable to protect proprietary/sensitive information. Interested parties shall not submit proprietary and/or sensitive information through Survey Monkey.

2.0 SUBJECT: The Congressionally Directed Medical Research Programs will hold a stakeholders meeting where individuals with relevant expertise and lived experience will be brought together to identify knowledge gaps, targeted outcomes and product needs that can advance the state of the science and improve patient care. To expedite the process, the CDMRP is currently requesting information on the identification of knowledge gaps, targeted outcomes and therapeutic needs that can advance the state of the science and improve patient care for individuals diagnosed with glioblastoma. The CDMRP will select stakeholders who respond to this RFI for invitation to attend the virtual stakeholders meeting. Response to this RFI does not guarantee an invitation.

3.0 BACKGROUND: According to the National Cancer Institute Surveillance, Epidemiology, and End Results, or SEERS, Program, glioblastoma affects three persons per 100,000 in the United States annually, making this cancer the most common type of brain cancer. The NCI Center for Cancer Research reports that glioblastoma is highly aggressive with a median survival of 15-18 months, while SEERS data demonstrates that only 6.2% of patients survive five years post diagnosis. A Glioblastoma Research Program, GBMRP, for fiscal year 2024 is included in the Consolidated Appropriations Act, 2024 at $10 million. The FY24 GBMRP will be managed by the CDMRP according to congressional intent. All CDMRP-funded research must be relevant to Service Members, their Families, Veterans and/or the American public.

CDMRP has developed a best-practices-based, flexible management cycle (https://cdmrp.health.mil/about/fundingprocess) that is responsive to the needs of both the individual programs and the requirements of the stakeholders for each program, including Congress, the DOD, researchers, patient communities and the American public. CDMRP will utilize this management cycle to administer the GBMRP. To initiate this process, CDMRP will hold a virtual GBMRP stakeholders meeting on 28 June 2024 where individuals with relevant expertise and experience will be brought together to identify knowledge gaps, targeted outcomes and therapeutic needs that can advance the state of the science and improve patient care. To set the stage for stakeholder discussions, this RFI is being used to solicit community input. Responses and subsequent meeting discussions are anticipated to inform the research landscape and identify opportunities for research. After the stakeholders meeting, a vision setting meeting will be held to recommend an investment strategy for the FY24 appropriation to answer some of the unmet medical needs, knowledge gaps and patient community concerns identified during the stakeholders meeting.

4.0 RESPONSE INSTRUCTIONS:

Please provide responses to the RFI below. It is anticipated that your input will take 10-15 minutes.

CDMRP is currently requesting information on the identification of knowledge gaps in areas of disease biology/etiology, diagnosis, prevention, interventions and patient needs in glioblastoma.

*Questions denoted with an asterisk are required. All other questions are optional.

1. *What area or topic within glioblastoma research do you feel holds the most promise to advance the field? Please limit each response to no more than 150 characters.

2. *In your opinion, which of the following areas is most underfunded/under-resourced in glioblastoma? Please choose a maximum of two.

· Prevention

· Treatment

· Etiology/Risk Factors

· Biology/Pathobiology

· Diagnosis and Prognosis

· Quality of Life

· Other (please state): __________

3. *The glioblastoma field would benefit from more ______ studies. Please choose a maximum of two.

· Initial Concepts/Early Ideas (basic research, new innovative ideas, high-risk:high-gain studies and novel, potentially groundbreaking concepts)

· Clinical/Translational (advancement of basic research studies; studies involving clinical specimens or existing human data)

· Team Science (multidisciplinary studies; collaborative efforts across multiple PIs and/or institutions)

· Clinical Trials (research studies in which one or more human subjects are prospectively assigned to one or more interventions – which may include a placebo or another control – to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes)

· Other (please state):____________

4. Please list a maximum of three innovative areas/topics that could revolutionize the course of glioblastoma research and/or clinical care.. Please limit each response to no more 250 characters.

5. What obstacles or challenges are researchers and the patient community facing that could potentially be addressed by the GBMRP? Examples could include: lack of research resources such as disease models or biobanks; difficulties with collaboration or data sharing; limited understanding of basic science; or patient access to clinical trials, etc. Please limit each response to no more than 250 characters.

6. Which of the following best describes your role in the glioblastoma community? Select all that apply.

· Academic Research Lab PI

· Industry Research Lab PI or Staff Researcher

· Glioblastoma Clinician

· Glioblastoma Patient/Caregiver/Advocate

· Foundation/Nonprofit

· Governmental Program Administrator

· Other (please specify)

7. If you would like to be contacted regarding attendance at the upcoming FY24 GBMRP Stakeholders Meeting (virtual meeting on 28 June 2024), please provide your name, organization, email address and phone number.

The GBMRP stakeholders meeting attendee list will be balanced across disciplines, as appropriate, to facilitate discussion. The CDMRP may not be able to accommodate all interested respondents. However, the outcomes of the GBMRP stakeholders meeting will be made publicly available on the GBMRP webpage.

Organization:

First name:

Last name:

Email address:

Phone number:

5.0 CONTACT INFORMATION: Any and all questions related to this RFI shall be directed to Beverly R. Michaels at beverly.r.michaels.civ@health.mil. Responses to the questions above shall be submitted to the link below by no later than 4:00 PM (EST) on 29 May 2024:

https://www.surveymonkey.com/r/FY24-GBMRP-RFI